This on-demand webinar shares our thoughts on evaluations for PD-1 inhibitors and assess some of the implications for manufacturers.
The points raised have broad oncology appeal as well as highlighting market access issues which have relevancy for rapidly evolving landscapes.
- Key emerging trends on market access
- How agencies are approaching assessments for melanoma, lung cancer and RCC
- Specific review of PD-1 testing in health technology assessments
- Explore the move in the treatment towards combination therapies
- David Sykes – Founding Partner
- Clare Jones – Director